Association between frailty and specific comorbidities on oncological outcomes in metastatic hormone-sensitive and castration resistant prostate cancer
Authors:
Open Access
- 23 January 2025
- journal article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 43 (6) , 397.e9-397.e16
Abstract
No abstract availableKeywords
All Related Versions
This publication has 27 references indexed in Scilit:
- Contemporary Treatment Patterns and Oncological Outcomes of Metastatic Hormone-sensitive Prostate Cancer and First- to Sixth- line Metastatic Castration-resistant Prostate Cancer PatientsEuropean Urology Open Science, 2024
- Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-analysis of Randomized Controlled TrialsClinical Genitourinary Cancer, 2024
- Risk of Fractures and Falls in Men with Advanced or Metastatic Prostate Cancer Receiving Androgen Deprivation Therapy and Treated with Novel Androgen Receptor Signalling Inhibitors: A Systematic Review and Meta-analysis of Randomised Controlled TrialsEuropean Urology Oncology, 2024
- The Burden of Uncontrolled Cardiovascular Risk Factors in Men With Prostate CancerJACC: Cardiooncology, 2023
- Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysisESMO Open, 2022
- Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysisEuropean Urology Focus, 2022
- Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysisEuropean Urology Focus, 2022
- Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patientsThe Prostate, 2021
- The effect of primary urological cancers on survival in men with secondary prostate cancerThe Prostate, 2021
- Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision OncologyEuropean Urology, 2019